Want to see RFL full AI Analyst Report?
Top Page
Rafael Holdings
(NYSE:RFL)
Select Model
Select Model
Rating:51Neutral
Price Target:
$2.00
▼(-10.71% Downside)
Action:Reiterated
Date:07/08/26
The score is held down primarily by very weak financial performance (persistent large losses and cash burn despite low leverage). Technicals are moderately supportive with improving momentum and price above key longer-term moving averages, and corporate events are a notable positive due to Phase 3 completion and expanded IP—partly offset by limited valuation support given ongoing losses and no dividend yield.
Positive Factors
Very low leverage
Minimal debt reduces refinancing pressure and interest burden, giving Rafael Holdings greater flexibility to fund biotechnology development and manage its real-estate interests while limiting balance-sheet risk.
Negative Factors
Small and declining revenue base
Very low and declining revenue indicates that the operating platform has not yet established meaningful commercial scale. This limits internal funding capacity and leaves results highly dependent on future biotechnology milestones or asset monetization.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
Minimal debt reduces refinancing pressure and interest burden, giving Rafael Holdings greater flexibility to fund biotechnology development and manage its real-estate interests while limiting balance-sheet risk.
Read all positive factors
Rafael Holdings (RFL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$133.15M
Dividend Yield0.82%
Average Volume (3M)103.55K
Price to Earnings (P/E)―
Beta (1Y)0.58
Revenue Growth33.88%
EPS Growth26.75%
CountryUS
Employees22
SectorReal Estate
Sector Strength53
IndustryReal Estate - Services
Share Statistics
EPS (TTM)-0.68
Shares Outstanding51,212,833
10 Day Avg. Volume121,409
30 Day Avg. Volume103,545
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.53
Price to Sales (P/S)54.22
P/FCF Ratio-2.63
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Rafael Holdings Business Overview & Revenue Model
Company Description
Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are str...
How the Company Makes Money
null...
Rafael Holdings Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Jul 2025 | Oct 2024 | Jul 2023 | Oct 2022 | Jul 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 980.00K | 917.00K | 637.00K | 279.00K | 410.00K | 802.00K |
| Gross Profit | 777.00K | 495.00K | 483.00K | 279.00K | 410.00K | 802.00K |
| EBITDA | -31.00M | -32.25M | -66.79M | -8.67M | -139.89M | -23.34M |
| Net Income | -32.55M | -30.52M | -34.41M | -1.88M | -124.66M | -24.54M |
Balance Sheet | ||||||
| Total Assets | 91.99M | 114.11M | 96.83M | 98.83M | 118.32M | 154.06M |
| Cash, Cash Equivalents and Short-Term Investments | 30.50M | 52.77M | 65.94M | 79.51M | 63.23M | 7.85M |
| Total Debt | 610.00K | 692.00K | 2.39M | 0.00 | 15.00M | 14.53M |
| Total Liabilities | 11.19M | 15.74M | 10.57M | 2.20M | 21.11M | 17.35M |
| Stockholders Equity | 75.39M | 94.39M | 82.19M | 100.29M | 100.52M | 122.29M |
Cash Flow | ||||||
| Free Cash Flow | -31.98M | -18.93M | -7.98M | 40.79M | -26.08M | -15.81M |
| Operating Cash Flow | -31.98M | -18.92M | -7.80M | -10.89M | -26.08M | -15.60M |
| Investing Cash Flow | -516.00K | 44.03M | -10.82M | 21.21M | -63.80M | -7.26M |
| Financing Cash Flow | 24.79M | 24.83M | -179.00K | -15.22M | 103.86M | 29.39M |
Rafael Holdings Technical Analysis
Positive
2.24
Price Trends
2.29
Positive
1.94
Positive
1.60
Positive
Market Momentum
0.12
Negative
63.91
Neutral
61.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RFL, the sentiment is Positive. The current price of 2.24 is above the 20-day moving average (MA) of 2.18, below the 50-day MA of 2.29, and above the 200-day MA of 1.60, indicating a bullish trend. The MACD of 0.12 indicates Negative momentum. The RSI at 63.91 is Neutral, neither overbought nor oversold. The STOCH value of 61.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RFL.
Rafael Holdings Risk Analysis
Rafael Holdings disclosed 78 risk factors in its most recent earnings report. Rafael Holdings reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Rafael Holdings Peers Comparison
UnderperformOutperform
Sector (65)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $2.17B | 12.19 | 3.79% | 4.94% | 3.15% | 1.96% | |
63 Neutral | $409.27M | -28.16 | -25.78% | ― | 38.44% | -12.22% | |
59 Neutral | $673.49M | -37.42 | -6.78% | 4.96% | 8.07% | 47.74% | |
54 Neutral | $8.54B | 103.54 | 3.63% | ― | 67.81% | ― | |
51 Neutral | $133.15M | -3.75 | -38.97% | 0.82% | 33.88% | 26.75% | |
51 Neutral | $164.51M | 6.96 | 15.69% | 6.66% | -2.75% | ― |
* Real Estate Sector Average
RFL
Rafael Holdings
2.56
1.12
77.78%
AGNT
eXp World Holdings
4.03
-6.69
-62.39%
REAX
Real Brokerage
18.67
-32.63
-63.61%
COMP
Compass
11.12
1.84
19.83%
DOUG
Douglas Elliman Inc.
1.81
-0.89
-32.96%
Rafael Holdings Corporate Events
Business Operations and StrategyProduct-Related Announcements
Rafael Holdings Completes Pivotal Phase 3 TransportNPC Study
Positive
Jun 10, 2026
On June 10, 2026, Rafael Holdings announced that the last patient completed the final 96-week visit in its pivotal Phase 3 TransportNPC study of Trappsol Cyclo for Niemann-Pick Disease Type C, involving 94 patients across 27 sites in 13 countries,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.